Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration
Authors
Keywords
-
Journal
BMC CANCER
Volume 20, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-08-31
DOI
10.1186/s12885-020-07313-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score
- (2019) Nathan I. Cherny et al. JOURNAL OF CLINICAL ONCOLOGY
- Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer
- (2018) David J. Vaughn et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
- (2018) Robert L. Ferris et al. ORAL ONCOLOGY
- Association of Immunotherapy With Durable Survival as Defined by Value Frameworks for Cancer Care
- (2018) Omer Ben-Aharon et al. JAMA Oncology
- Are Value Frameworks Missing the Mark When Considering Long-term Benefits From Immuno-oncology Drugs?
- (2018) Lowell E. Schnipper et al. JAMA Oncology
- Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057
- (2018) Martin Reck et al. EUROPEAN JOURNAL OF CANCER
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
- (2018) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improving on Tail-of-the-Curve Evaluation With the American Society of Clinical Oncology Value Framework
- (2018) Alexandre Vivot et al. JAMA Oncology
- Five years of EMA-approved systemic cancer therapies for solid tumours—a comparison of two thresholds for meaningful clinical benefit
- (2017) N. Grössmann et al. EUROPEAN JOURNAL OF CANCER
- Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit?
- (2017) Sierra Cheng et al. JOURNAL OF CLINICAL ONCOLOGY
- Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration
- (2017) Ariadna Tibau et al. JNCI-Journal of the National Cancer Institute
- Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial
- (2017) Julie R Brahmer et al. LANCET ONCOLOGY
- Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks
- (2017) Joseph C Del Paggio et al. LANCET ONCOLOGY
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration
- (2017) Ariadna Tibau et al. JNCI-Journal of the National Cancer Institute
- Exploration of the ASCO and ESMO Value Frameworks for Antineoplastic Drugs
- (2017) Daniel J. Becker et al. Journal of Oncology Practice
- Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study
- (2016) G. V. Long et al. ANNALS OF ONCOLOGY
- Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received
- (2016) Lowell E. Schnipper et al. JOURNAL OF CLINICAL ONCOLOGY
- Patient-reported outcomes in the evaluation of toxicity of anticancer treatments
- (2016) Massimo Di Maio et al. Nature Reviews Clinical Oncology
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
- (2015) N. I. Cherny et al. ANNALS OF ONCOLOGY
- American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options
- (2015) Lowell E. Schnipper et al. JOURNAL OF CLINICAL ONCOLOGY
- Patient-reported outcomes as end points and outcome indicators in solid tumours
- (2015) Angeles A. Secord et al. Nature Reviews Clinical Oncology
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started